Stanley Capital Partners completed the acquisition of a majority stake in Laboratoire XO.

Stanley Capital Partners, a private equity firm, completed the acquisition of a majority stake in Laboratoire XO, a French pharmaceutical group. Financial terms were not disclosed. "SCP is pleased to partner with Karine Pinon and her impressive management team to accelerate Lab XO’s growth with a global footprint. All parties share a vision to couple further acquisitive growth with building leading lifecycle management capabilities to create a formidable specialist pharma player providing essential medicines to its customers in the patient community," Simon Cottle, SCP Founding Partner.